Summary

Plasma Fractionation Market – Scope of Report
TMR’s report on the global plasma fractionation market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global plasma fractionation market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global plasma fractionation market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the plasma fractionation market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global plasma fractionation market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global plasma fractionation market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global plasma fractionation market.

The report delves into the competitive landscape of the global plasma fractionation market. Key players operating in the global plasma fractionation market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global plasma fractionation market profiled in this report.

Key Questions Answered in Global plasma fractionation Market Report
• What is the sales/revenue generated by plasma fractionation across all regions during the forecast period?
• What are the opportunities in the global plasma fractionation market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Plasma Fractionation Market – Research Objectives and Research Approach
The comprehensive report on the global plasma fractionation market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global plasma fractionation market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global plasma fractionation market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Plasma Fractionation Market
4. Market Overview
4.1. Introduction
4.1.1. Technology, Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Plasma Fractionation Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Technology, /Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Plasma Fractionation Market Analysis and Forecast, by Product Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product Type, 2017–2031
6.3.1. Immunoglobulin
6.3.1.1. Intravenous Immunoglobulin
6.3.1.2. Subcutaneous Immunoglobulin
6.3.2. Coagulation Factor Concentrates
6.3.2.1. Factor VIII
6.3.2.2. Factor IX
6.3.2.3. Factor XIII
6.3.2.4. Prothrombin Complex Concentrates
6.3.2.5. Von Willebrand Factor (VWF)
6.3.2.6. Fibrinogen Concentrates
6.3.3. Albumin
6.3.4. Protease Inhibitors
6.3.5. Other Plasma Products
6.4. Market Attractiveness Analysis, by Product Type,
7. Plasma Fractionation Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Application, 2017–2031
7.3.1. Neurology
7.3.2. Immunology
7.3.3. Hematology
7.3.4. Critical Care
7.3.5. Pulmonology
7.3.6. Others
7.4. Market Attractiveness Analysis, by Application
8. Plasma Fractionation Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2017–2031
8.3.1. Hospitals and Clinics
8.3.2. Clinical Research Laboratories
8.3.3. Academic Institutes
8.4. Market Attractiveness Analysis, by Application
9. Plasma Fractionation Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Plasma Fractionation Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Product Type, 2017–2031
10.3.1. Immunoglobulin
10.3.1.1. Intravenous Immunoglobulin
10.3.1.2. Subcutaneous Immunoglobulin
10.3.2. Coagulation Factor Concentrates
10.3.2.1. Factor VIII
10.3.2.2. Factor IX
10.3.2.3. Factor XIII
10.3.2.4. Prothrombin Complex Concentrates
10.3.2.5. Von Willebrand Factor (VWF)
10.3.2.6. Fibrinogen Concentrates
10.3.3. Albumin
10.3.4. Protease Inhibitors
10.3.5. Other Plasma Products
10.4. Market Value Forecast, by Application, 2017–2031
10.4.1. Neurology
10.4.2. Immunology
10.4.3. Hematology
10.4.4. Critical Care
10.4.5. Pulmonology
10.4.6. Others
10.5. Market Value Forecast, by End-user, 2017–2031
10.5.1. Hospitals and Clinics
10.5.2. Clinical Research Laboratories
10.5.3. Academic Institutes
10.6. Market Value Forecast, by Country, 2017–2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Product Type,
10.7.2. By Application
10.7.3. By End-user
10.7.4. By Country
11. Europe Plasma Fractionation Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Product Type, 2017–2031
11.3.1. Immunoglobulin
11.3.1.1. Intravenous Immunoglobulin
11.3.1.2. Subcutaneous Immunoglobulin
11.3.2. Coagulation Factor Concentrates
11.3.2.1. Factor VIII
11.3.2.2. Factor IX
11.3.2.3. Factor XIII
11.3.2.4. Prothrombin Complex Concentrates
11.3.2.5. Von Willebrand Factor (VWF)
11.3.2.6. Fibrinogen Concentrates
11.3.3. Albumin
11.3.4. Protease Inhibitors
11.3.5. Other Plasma Products
11.4. Market Value Forecast, by Application, 2017–2031
11.4.1. Neurology
11.4.2. Immunology
11.4.3. Hematology
11.4.4. Critical Care
11.4.5. Pulmonology
11.4.6. Others
11.5. Market Value Forecast, by End-user, 2017–2031
11.5.1. Hospitals and Clinics
11.5.2. Clinical Research Laboratories
11.5.3. Academic Institutes
11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Product Type
11.7.2. By Application
11.7.3. By End-user
11.7.4. By Country/Sub-region
12. Asia Pacific Plasma Fractionation Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Product Type, 2017–2031
12.3.1. Immunoglobulin
12.3.1.1. Intravenous Immunoglobulin
12.3.1.2. Subcutaneous Immunoglobulin
12.3.2. Coagulation Factor Concentrates
12.3.2.1. Factor VIII
12.3.2.2. Factor IX
12.3.2.3. Factor XIII
12.3.2.4. Prothrombin Complex Concentrates
12.3.2.5. Von Willebrand Factor (VWF)
12.3.2.6. Fibrinogen Concentrates
12.3.3. Albumin
12.3.4. Protease Inhibitors
12.3.5. Other Plasma Products
12.4. Market Value Forecast, by Application, 2017–2031
12.4.1. Neurology
12.4.2. Immunology
12.4.3. Hematology
12.4.4. Critical Care
12.4.5. Pulmonology
12.4.6. Others
12.5. Market Value Forecast, by End-user, 2017–2031
12.5.1. Hospitals and Clinics
12.5.2. Clinical Research Laboratories
12.5.3. Academic Institutes
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Product Type,
12.7.2. By Application
12.7.3. By End-user
12.7.4. By Country/Sub-region
13. Latin America Plasma Fractionation Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Product Type, 2017–2031
13.3.1. Immunoglobulin
13.3.1.1. Intravenous Immunoglobulin
13.3.1.2. Subcutaneous Immunoglobulin
13.3.2. Coagulation Factor Concentrates
13.3.2.1. Factor VIII
13.3.2.2. Factor IX
13.3.2.3. Factor XIII
13.3.2.4. Prothrombin Complex Concentrates
13.3.2.5. Von Willebrand Factor (VWF)
13.3.2.6. Fibrinogen Concentrates
13.3.3. Albumin
13.3.4. Protease Inhibitors
13.3.5. Other Plasma Products
13.4. Market Value Forecast, by Application, 2017–2031
13.4.1. Neurology
13.4.2. Immunology
13.4.3. Hematology
13.4.4. Critical Care
13.4.5. Pulmonology
13.4.6. Others
13.5. Market Value Forecast, by End-user, 2017–2031
13.5.1. Hospitals and Clinics
13.5.2. Clinical Research Laboratories
13.5.3. Academic Institutes
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Product Type,
13.7.2. By Application
13.7.3. By End-user
13.7.4. By Country/Sub-region
14. Middle East & Africa Plasma Fractionation Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Product Type, 2017–2031
14.3.1. Immunoglobulin
14.3.1.1. Intravenous Immunoglobulin
14.3.1.2. Subcutaneous Immunoglobulin
14.3.2. Coagulation Factor Concentrates
14.3.2.1. Factor VIII
14.3.2.2. Factor IX
14.3.2.3. Factor XIII
14.3.2.4. Prothrombin Complex Concentrates
14.3.2.5. Von Willebrand Factor (VWF)
14.3.2.6. Fibrinogen Concentrates
14.3.3. Albumin
14.3.4. Protease Inhibitors
14.3.5. Other Plasma Products
14.4. Market Value Forecast, by Application, 2017–2031
14.4.1. Neurology
14.4.2. Immunology
14.4.3. Hematology
14.4.4. Critical Care
14.4.5. Pulmonology
14.4.6. Others
14.5. Market Value Forecast, by End-user, 2017–2031
14.5.1. Hospitals and Clinics
14.5.2. Clinical Research Laboratories
14.5.3. Academic Institutes
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Product Type,
14.7.2. By Application
14.7.3. By End-user
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. CSL Limited
15.3.1.1. Company Overview
15.3.1.2. Technology, Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Takeda Pharmaceutical Company
15.3.2.1. Company Overview
15.3.2.2. Technology, Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Sanquin
15.3.3.1. Company Overview
15.3.3.2. Technology, Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Biotest AG
15.3.4.1. Company Overview
15.3.4.2. Technology, Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. GRIFOLS
15.3.5.1. Company Overview
15.3.5.2. Technology, Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Baxter International Inc.
15.3.6.1. Company Overview
15.3.6.2. Technology, Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Kedrion
15.3.7.1. Company Overview
15.3.7.2. Technology, Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Octapharma AG
15.3.8.1. Company Overview
15.3.8.2. Technology, Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Taibang Biological Group Co., Ltd
15.3.9.1. Company Overview
15.3.9.2. Technology, Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview